V943
Biological
Merck Sharp & Dohme Corporation
Total Payments
$194,279
Transactions
3
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $194,279 | 3 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $194,279 | 3 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 1, Open_label Clinical Trial Evaluating the Safety, Tolerability, and Immunogenicity of Intradermally Administered ID-LV305 in Patients with Locally Advanced or Metastatic Cancer Expressing NY-ESO-1 | Merck Sharp & Dohme Corporation | $173,657 | 0 |
| A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Determine the Efficacy and Safety of CMB305 in Unresectable Locally-advanced or Metastatic NY-ESO-1 Synovial Sarcoma Subjects Following First-line Systemic Anti-cancer Therapy | Merck Sharp & Dohme Corporation | $20,622 | 0 |
Top Doctors Receiving Payments for V943
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Dallas, TX | $194,279 | 3 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $194,279
Product Information
- Type Biological
- Total Payments $194,279
- Total Doctors 0
- Transactions 3
About V943
V943 is a biological associated with $194,279 in payments to 0 healthcare providers, recorded across 3 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2020 to 2020. In 2020, $194,279 was paid across 3 transactions to 0 doctors.
The most common payment nature for V943 is "Unspecified" ($194,279, 100.0% of total).
V943 is associated with 2 research studies, including "A Phase 1, Open_label Clinical Trial Evaluating the Safety, Tolerability, and Immunogenicity of Intradermally Administered ID-LV305 in Patients with Locally Advanced or Metastatic Cancer Expressing NY-ESO-1" ($173,657).